

# Tarek A Bismar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6793273/publications.pdf>

Version: 2024-02-01

68  
papers

3,462  
citations

185998

28  
h-index

138251

58  
g-index

71  
all docs

71  
docs citations

71  
times ranked

5394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	15.2	436
2	TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion. <i>American Journal of Surgical Pathology</i> , 2007, 31, 882-888.	2.1	394
3	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal Treatment-Related Neuroendocrine Prostate Cancer. <i>Neoplasia</i> , 2013, 15, 1-14.	2.3	205
4	Characterization of <i>TMPRSS2-ERG</i> Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications. <i>Clinical Cancer Research</i> , 2008, 14, 3380-3385.	3.2	200
5	<i>PTEN</i> genomic deletion is associated with <i>Akt</i> and AR signalling in poorer outcome, hormone refractory prostate cancer. <i>Journal of Pathology</i> , 2009, 218, 505-513.	2.1	196
6	Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. <i>Journal of Experimental Medicine</i> , 2010, 207, 2421-2437.	4.2	146
7	A Novel Experimental Heme Oxygenase-1-Targeted Therapy for Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 8017-8024.	0.4	110
8	Decreased <i>Methylcronyl CoA Racemase</i> Expression in Localized Prostate Cancer is Associated with an Increased Rate of Biochemical Recurrence and Cancer-Specific Death. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1424-1432.	1.1	105
9	<i>PTEN</i> genomic deletion is an early event associated with <i>ERG</i> gene rearrangements in prostate cancer. <i>BJU International</i> , 2011, 107, 477-485.	1.3	99
10	Fascin Regulates Prostate Cancer Cell Invasion and Is Associated with Metastasis and Biochemical Failure in Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1376-1383.	3.2	91
11	Defining Aggressive Prostate Cancer Using a 12-Gene Model. <i>Neoplasia</i> , 2006, 8, 59-68.	2.3	90
12	Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer. <i>American Journal of Pathology</i> , 2012, 180, 895-903.	1.9	72
13	<i>PTEN</i> deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. <i>Journal of Pathology</i> , 2011, 224, 90-100.	2.1	62
14	TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort. <i>Cancer Biology and Therapy</i> , 2009, 8, 125-130.	1.5	59
15	ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. <i>European Journal of Cancer</i> , 2012, 48, 538-546.	1.3	58
16	Focal Adhesion Kinase-Related Proline-Rich Tyrosine Kinase 2 and Focal Adhesion Kinase Are Co-Overexpressed in Early-Stage and Invasive ErbB-2-Positive Breast Cancer and Cooperate for Breast Cancer Cell Tumorigenesis and Invasiveness. <i>American Journal of Pathology</i> , 2008, 173, 1540-1550.	1.9	57
17	<i>PTEN</i> genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 149-160.	1.5	53
18	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 399-405.	2.0	53

#	ARTICLE	IF	CITATIONS
19	Interactions and relationships of <i>PTEN</i> , <i>ERG</i> , <i>SPINK1</i> and <i>AR</i> in castration-resistant prostate cancer. <i>Histopathology</i> , 2012, 60, 645-652.	1.6	52
20	ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression. <i>Neoplasia</i> , 2010, 12, 1031-IN22.	2.3	51
21	Role of the EphB2 receptor in autophagy, apoptosis and invasion in human breast cancer cells. <i>Experimental Cell Research</i> , 2014, 320, 233-246.	1.2	46
22	Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. <i>Cancer Research</i> , 2016, 76, 1603-1614.	0.4	40
23	Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. <i>American Journal of Surgical Pathology</i> , 2020, 44, e15-e29.	2.1	40
24	<i>TMPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. <i>Clinical Cancer Research</i> , 2013, 19, 5202-5209.	3.2	39
25	Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 136-143.	2.0	36
26	Detection of <i>ERG</i> gene rearrangements and <i>PTEN</i> deletions in unsuspected prostate cancer of the transition zone. <i>Cancer Biology and Therapy</i> , 2011, 11, 562-566.	1.5	35
27	Elevated physiological levels of folic acid can increase <i>in vitro</i> growth and invasiveness of prostate cancer cells. <i>BJU International</i> , 2012, 109, 788-795.	1.3	35
28	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	1.3	35
29	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. <i>Journal of Urology</i> , 2022, 207, 541-550.	0.2	30
30	The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. <i>Cancer Medicine</i> , 2014, 3, 14-24.	1.3	28
31	<i>ING3</i> promotes prostate cancer growth by activating the androgen receptor. <i>BMC Medicine</i> , 2017, 15, 103.	2.3	27
32	Cysteine- rich secretory protein 3 (CRISP3), <i>ERG</i> and <i>PTEN</i> define a molecular subtype of prostate cancer with implication to patients' prognosis. <i>Journal of Hematology and Oncology</i> , 2014, 7, 21.	6.9	25
33	Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 883-891.	1.2	24
34	<i>ERG</i> Protein Expression and Gene Rearrangements Are Present at Lower Rates in Metastatic and Locally Advanced Castration-resistant Prostate Cancer Compared to Localized Disease. <i>Urology</i> , 2013, 82, 394-399.	0.5	22
35	Interrogation of <i>ERG</i> gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome. <i>BJU International</i> , 2014, 113, 309-319.	1.3	22
36	Insights into a novel nuclear function for Fascin in the regulation of the amino-acid transporter <i>SLC3A2</i> . <i>Scientific Reports</i> , 2016, 6, 36699.	1.6	22

#	ARTICLE	IF	CITATIONS
37	Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients. <i>Journal of Molecular Medicine</i> , 2016, 94, 1411-1422.	1.7	21
38	Quantitative in vivo whole genome motility screen reveals novel therapeutic targets to block cancer metastasis. <i>Nature Communications</i> , 2018, 9, 2343.	5.8	21
39	ERG Expression in Prostate Needle Biopsy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 499-505.	0.6	19
40	Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2117-2125.	1.2	19
41	Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 3453-3461.	2.3	18
42	Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. <i>BJU International</i> , 2010, 106, 418-423.	1.3	17
43	SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 235.e1-235.e10.	0.8	17
44	Prostate Epithelium-Specific Deletion of the Selenocysteine tRNA Gene <i>Trsp</i> Leads to Early Onset Intraepithelial Neoplasia. <i>American Journal of Pathology</i> , 2014, 184, 871-877.	1.9	16
45	High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer. <i>Tumor Biology</i> , 2016, 37, 12287-12299.	0.8	16
46	The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4772.	1.8	16
47	ING3 protein expression profiling in normal human tissues suggest its role in cellular growth and self-renewal. <i>European Journal of Cell Biology</i> , 2015, 94, 214-222.	1.6	15
48	Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, <i>ETV1</i> , and <i>ETV4</i> on whole-mount radical prostatectomy tissue. <i>Prostate</i> , 2020, 80, 38-50.	1.2	15
49	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 262-268.	0.8	15
50	ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients. <i>Tumor Biology</i> , 2016, 37, 9731-9738.	0.8	14
51	ERG expression in prostate cancer: biological relevance and clinical implication. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1781-1793.	1.2	14
52	DNA methylation signatures of Prostate Cancer in peripheral T-cells. <i>BMC Cancer</i> , 2020, 20, 588.	1.1	13
53	ERG Protein Expression Is of Limited Prognostic Value in Men with Localized Prostate Cancer. <i>ISRN Urology</i> , 2013, 2013, 1-6.	1.5	12
54	microRNA 338-3p exhibits tumor suppressor role and its down-regulation is associated with adverse clinical outcome in prostate cancer patients. <i>Molecular Biology Reports</i> , 2016, 43, 229-240.	1.0	12

#	ARTICLE	IF	CITATIONS
55	The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 1120-1128.	1.5	11
56	SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion. <i>Pathology and Oncology Research</i> , 2017, 23, 399-407.	0.9	9
57	ATM-deficient lung, prostate and pancreatic cancer cells are acutely sensitive to the combination of olaparib and the ATR inhibitor AZD6738. <i>Genome Instability &amp; Disease</i> , 2020, 1, 197-205.	0.5	9
58	Coordinate MicroRNA-Mediated Regulation of Protein Complexes in Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e84261.	1.1	9
59	Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1751-1759.	1.2	8
60	High Serine-arginine Protein Kinase 1 Expression with PTEN Loss Defines Aggressive Phenotype of Prostate Cancer Associated with Lethal Outcome and Decreased Overall Survival. <i>European Urology Open Science</i> , 2021, 23, 1-8.	0.2	7
61	ARPC1B Is Associated with Lethal Prostate Cancer and Its Inhibition Decreases Cell Invasion and Migration In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1476.	1.8	6
62	Decreased ATM Protein Expression Is Substantiated with PTEN Loss in Defining Aggressive Phenotype of Prostate Cancer Associated with Lethal Disease. <i>European Urology Open Science</i> , 2021, 29, 93-101.	0.2	5
63	Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2223-2231.	1.2	4
64	Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1701-1709.	1.2	3
65	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
66	Copy Number Profiles of Prostate Cancer in Men of Middle Eastern Ancestry. <i>Cancers</i> , 2021, 13, 2363.	1.7	1
67	Functional characterization of miRNAs in prostate cancer using functional protein networks. , 2012, , .		0
68	Tubulovillous Adenoma in the Bladder in a Dual Pancreas-Kidney Transplant Patient. <i>Journal of Endourology Case Reports</i> , 2017, 3, 17-20.	0.3	0